Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Location status: Recruiting
Location contact
Abimbola Akinniyi
CONTACT
Sydney Montesi, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT05417776
The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen deposition in early interstitial lung disease.
Interested in participating?
Request Info40 year and older
All sexes
Interventional
Phase 2
Boston, Massachusetts, 02114, United States
Location status: Recruiting
Abimbola Akinniyi
CONTACT
Sydney Montesi, MD
PRINCIPAL_INVESTIGATOR
[68Ga]CBP8, is a PET imaging probe which selectively binds collagen type I. Collagen deposition is a pivotal event in the development of pulmonary fibrosis. [68Ga]CBP8 binds collagen with high affinity and has excellent pharmacological and pharmacokinetic profiles. [68Ga]CBP8 was shown in a mouse model to be effective for detecting lung fibrosis and response to treatment. In addition, [68Ga]CBP8 can detect increased collagen in the lungs of patients with idiopathic pulmonary fibrosis.
The goals of this study are:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Group 1: First degree relatives of a family member with pulmonary fibrosis (n=8)
Group 2: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) (n=22)
Exclusion criteria
An injection of up to 350 MBq of [68Ga]CBP8 will be administered intravenously followed by PET-MRI.
Dotarem will be administered during MRI portion of study.
Other names: gadoterate meglumine
Time frame: 24 months
The degree of uptake of [68Ga]CBP8 in the lungs will be compared between groups and associations with disease severity and progression will be determined.
Time frame: 24 months
Kwashout rates will be compared between groups and associations with disease severity, progression, and degree of uptake of [68Ga]CBP8 will be determined.
Time frame: 24 months
Kwashin rates will be compared between groups and associations with disease severity, progression, and degree of uptake of [68Ga]CBP8 will be determined.
Time frame: 24 months
Peak enhancement will be compared between groups and associations with disease severity, progression, and degree of uptake of [68Ga]CBP8 will be determined.
Contact information is provided by the study sponsor or research team.
Abimbola Akinniyi
CONTACT
Sydney B Montesi, MD
CONTACT
Massachusetts General Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07613099
Acute Lung Injury, Allogeneic Stem Cell Transplantation
Bethesda, Maryland, United States
View Trial DetailsNCT06325696
Fibrosis, Idiopathic Pulmonary Fibrosis
Research Triangle Park, North Carolina, United States
View Trial DetailsNCT07561034
Cardiovascular Diseases, Hypertension
Rochester, New York, United States
View Trial DetailsNCT07512687
Chronic Disease, Chronic Obstructive Pulmonary Disease
Buffalo, New York, United States
View Trial Details